aTyr Pharma announced that the company will present data on the mechanism of action, MOA, and exposure-efficacy analysis for its lead therapeutic candidate, efzofitimod, in an oral symposia presentation and poster session, respectively, at the American Thoracic Society, ATS, 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC. "These abstracts highlight the important data we continue to generate for efzofitimod and our clinical program in pulmonary sarcoidosis, a major form of interstitial lung disease with high unmet medical need," said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. "We look forward to presenting groundbreaking data around efzofitimod’s MOA and its ability to modulate myeloid cells, which represents an advancement in our mechanistic understanding of how efzofitimod is demonstrating the clinical benefit seen in a Phase 1b/2a study in patients with pulmonary sarcoidosis. Additionally, an exposure-efficacy analysis of efzofitimod provides further confirmatory evidence of clinical proof-of-concept from our previous study."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIFE:
- aTyr: EPO okays use of efzofitimod with pirfenidone patent for lung inflammation
- aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
- EC grants aTyr Pharma ODA to efzofitimod to treat sarcoidosis
- European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
- aTyr Pharma announces LTBP1 as target of DARS tRNA synthetase fragment
